- Home
- CTW vs ACOG Comparison
CTW vs ACOG Comparison
Compare CTW & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTW | ACOG |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | Japan | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 193.6M |
| IPO Year | 2025 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CTW | ACOG |
|---|---|---|
| Price | $2.34 | $8.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 23.4K | ★ 162.7K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,220,275.00 |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $4.50 |
| 52 Week High | $3.14 | $10.14 |
Technical Indicators
Market Signals| Indicator | CTW | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 47.57 |
| Support Level | $2.00 | $5.28 |
| Resistance Level | $2.58 | $9.04 |
| Average True Range (ATR) | 0.29 | 0.55 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 0.76 | 3.91 |
Price Performance
Historical ComparisonAbout CTW CTW Cayman Class A Ordinary Shares
CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.
About ACOG Alpha Cognition Inc.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.